Aviragen Therapeutics Inc Stock Nasdaq
Stocks
US0537611024
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 149M 130M 120M 111M 212M 14.2B 215M 1.44B 559M 6.97B 559M 547M 24.17B | P/E 2026 * |
2.13x | P/E 2027 * | -0.64x |
|---|---|---|---|---|---|
| Enterprise Value | 149M 130M 120M 111M 212M 14.2B 215M 1.44B 559M 6.97B 559M 547M 24.17B | EV / Sales 2026 * |
0.42x | EV / Sales 2027 * | - |
| Free-Float |
98.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aviragen Therapeutics Inc
| 1 day | -8.47% |
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Lo
CEO | Chief Executive Officer | 60 | 2024-03-17 |
Sean Tucker
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-02-29 |
Jeroen Grasman
DFI | Director of Finance/CFO | - | 2025-05-18 |
| Director | Title | Age | Since |
|---|---|---|---|
David Wheadon
BRD | Director/Board Member | 68 | 2021-04-20 |
William Watson
BRD | Director/Board Member | 76 | 2022-08-03 |
Elaine Heron
BRD | Director/Board Member | 79 | 2021-03-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.47% | +1,187.88% | - | - | 149M | |
| -0.10% | +0.10% | +74.33% | +133.26% | 57.73B | |
| -3.80% | -6.24% | +67.04% | +86.36% | 54.69B | |
| +0.10% | +0.67% | -14.88% | -12.34% | 23.75B | |
| +1.40% | +5.92% | +16.48% | +468.63% | 24.18B | |
| -2.70% | +4.25% | +40.38% | -3.72% | 19.82B | |
| +3.78% | +5.65% | +44.99% | -26.23% | 17.14B | |
| +3.46% | +17.72% | +206.66% | +364.07% | 16.75B | |
| -1.81% | +18.00% | +41.99% | - | 15.57B | |
| +3.12% | +5.17% | +29.59% | +196.35% | 13.96B | |
| Average | -0.51% | +5.56% | +56.29% | +150.80% | 27.06B | |
| Weighted average by Cap. | -0.39% | +3.34% | +57.90% | +139.33% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 356M 312M 287M 266M 506M 33.95B 513M 3.44B 1.34B 16.66B 1.34B 1.31B 57.78B | - |
| Net income | 116M 102M 93.57M 86.86M 165M 11.06B 167M 1.12B 436M 5.43B 436M 426M 18.83B | -284M -249M -229M -213M -404M -27.09B -409M -2.74B -1.07B -13.3B -1.07B -1.04B -46.1B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
